This oak tree has stood in this very spot since long before he or I walked the Earth. It is early winter when MacKenzie, an atmospheric scientist and director of Birmingham University Institute ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures ...

AngioDynamics (ANGO) is scheduled to report earnings on April 3, 2025. The last reported earnings were for reported on January 8, 2025 for Q2.

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...